METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTITATIVE ESTIMATION OF ACAMPROSATE CALCIUM IN TABLETS USING RP-HPLC

  • Jeevitha Nimma Department of Pharmaceutical analysis and Quality Assurance, Vijaya College of pharmacy, Munaganur (village), Hayathnagar (Mandal), Hyderabad 501511, India.
  • Rajesh Tuniki Department of Pharmaceutical analysis and Quality Assurance, Vijaya College of pharmacy, Munaganur (village), Hayathnagar (Mandal), Hyderabad 501511, India.
  • Sowjanya Kumari Andela Department of Pharmaceutical analysis and Quality Assurance, Vijaya College of pharmacy, Munaganur (village), Hayathnagar (Mandal), Hyderabad 501511, India.
  • Sumedh Gadpale Department of Pharmaceutical analysis and Quality Assurance, Vijaya College of pharmacy, Munaganur (village), Hayathnagar (Mandal), Hyderabad 501511, India.
  • Ashok Kumar Akuthota Department of Pharmaceutical analysis and Quality Assurance, Vijaya College of pharmacy, Munaganur (village), Hayathnagar (Mandal), Hyderabad 501511, India.

Abstract

Objective: To develop an accurate, precise and linear Reverse Phase High Performance Liquid Chromatographic (RP-HPLC) method and validate as per ICH guidelines for the quantitative estimation of Acamprosate calcium (333 mg) in tablets.

Methods: The optimized method uses a reverse phase column, Enable Make C18G (250 X 4.6 mm; 5μ), a mobile phase of triethylammonium phosphate buffer (pH 3.0): acetonitrile in the proportion of 30:70 v/v, flow rate of 1.0 ml/min and a detection wavelength of 210 nm using a UV detector.

Results: The developed method resulted in Acamprosate calcium eluting at 2.36 min. Acamprosate calcium exhibited linearity in the range 75-225μg/ml. The precision is exemplified by relative standard deviation of 0.149%. Percentage Mean recovery was found to be in the range of 98â€102, during accuracy studies. The limit of detection (LOD) and limit of quantitiation (LOQ) was found to be 570 ng/ml and 1729 ng/ml respectively.

Conclusion: An accurate, precise and linear RP-HPLC method was developed and validated for the quantitative estimation of Acamprosate calcium 333 mg in tablets as per ICH guidelines and hence it can be used for routine analysis in various pharmaceutical industries.

 

Keywords: RP‐HPLC, Acamprosate calcium, Method development, Validation.

Downloads

Download data is not yet available.

Author Biographies

Jeevitha Nimma, Department of Pharmaceutical analysis and Quality Assurance, Vijaya College of pharmacy, Munaganur (village), Hayathnagar (Mandal), Hyderabad 501511, India.
Department of Pharmaceutical Analysis and Quality assurance
Rajesh Tuniki, Department of Pharmaceutical analysis and Quality Assurance, Vijaya College of pharmacy, Munaganur (village), Hayathnagar (Mandal), Hyderabad 501511, India.
Department of Pharmaceutical Analysis and Quality assurance
Sowjanya Kumari Andela, Department of Pharmaceutical analysis and Quality Assurance, Vijaya College of pharmacy, Munaganur (village), Hayathnagar (Mandal), Hyderabad 501511, India.
Department of Pharmaceutical Analysis and Quality assurance
Sumedh Gadpale, Department of Pharmaceutical analysis and Quality Assurance, Vijaya College of pharmacy, Munaganur (village), Hayathnagar (Mandal), Hyderabad 501511, India.
Department of Pharmaceutical Analysis and Quality assurance
Ashok Kumar Akuthota, Department of Pharmaceutical analysis and Quality Assurance, Vijaya College of pharmacy, Munaganur (village), Hayathnagar (Mandal), Hyderabad 501511, India.
Department of Pharmaceutical Analysis and Quality assurance

References

1. Zornoza T, Cano MJ, Polache A, Granero L. Pharmacology of acamprosate: an overview. CNS Drug Rev 2003;9(4):359-74.
2. Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998;35(5):331-45.
3. Rhee YS, Park S, Lee TW, Park CW, Nam TY, Oh TO, et al. Investigation of the relationship between in vitro and in vivo release behaviors of acamprosate from enteric-coated tablets. Arch Pharm Res 2008;31(6):798-804.
4. Espino D, Cruz MP. Acamprosate calcium (ACAMPROL®): An effective treatment for maintaining abstinence in alcohol-dependent patients in combination with psychosocial support. Pharm Therapeutics 2005;30:497-505.
5. Lipha Pharmaceuticals Inc. Briefing Document for Acamprosate 333 mg Tablets. Food and Drug Administration: Washington, DC, US; 2002:1-311.
6. Blanchin MD, Baalbak B, Bosc N, Fabre H. Short-end injection technique in capillary electrophoresis for dissolution testing of tablets. Anal Chim Acta 2000;415:67-73.
7. Fabre H, Perrin C, Bosc N. Determination of homotaurine as impurity in calcium acamprosate by capillary zone electrophoresis. J Chromatogr A 1999;853:421-30.
8. Chabenat C, Ladure P, Blanc-Continsouza D, Boismare F, Boucly P. Determination of calcium acetylhomotaurinate by liquid chromatography with fluorimetric and electrochemical detection. J Chromatogr B Biomed Sci Appl 1987;414:417-22.
9. Chabenat C, Ladure P, Moore N, Boucly P, Boismare F. Application of an analytical method to calcium acetylhomotaurinate determination in urine. Arzneimittelforschung 1989;39:1413-4.
10. Girault J, Gobin P, Fourtillan JB. Determination of calcium acetylhomotaurinate in human plasma and urine by combined gas chromatography-negative-ion chemical ionization mass spectrometry. J Chromatogr 1990;530:295-305.
11. Rhee YS, Park JH, Park S, Park CW, Ha JM, Jeong KW, et al. Analysis of Acamprosate in Beagle Dog Plasma by LC-MS-MS. Arch Pharm Res 2008;31:1035-9.
12. Xu F, Quing Y, Shang B, Liang M, Zou Y, Xu G. Pharmacokinetics of acamprosate calcium in healthy chinese subjects after oral administration of three dosage levels. Arzneimittelforschung 2009;59:631-4.
13. Ghosh C, Jha V, Shinde CP, Chakraborty BS. A LC-MS analysis of acamprosate from human plasma: pharmacokinetic application. Drug Test Anal 2011;3(10):735-42.
14. Hammarberg A, Beck O, Eksborg S, Jayaram-Lindström N, Lindefeldt A, Andersson M, Brundin L, et al. Acamprosate determinations in plasma and cerebrospinal fluid after multiple dosing measured by liquid chromatography-mass spectroscopy: a pharmacokinetic study in healthy volunteers. Ther Drug Monit 2010;32(4):489-96.
15. Rhee YS, Park JH, Park S, Park CW, Ha JM, Jeong KW, Lee DS, et al. Analysis of acamprosate in beagle dog plasma by LC-MS-MS. Arch Pharm Res 2008;31(8):1035-9.
16. Kanchana Mala K, Babu Rao C, Nagiat TH, Mukkanti K, Prakash K, Challa BR. Quantification of Acamprosate in human plasma by LC-ESIMS/ MS with solid phase extraction: application to a bioequivalence study. J Pharm Res 2013;7:389-96.
17. Babua C, Sreenivasa Rao B, Suresh Reddy KVN, Naganjaneyulu B. Development and validation of HPLC assay method for the acamprosate ca in commercial tablets. Indian J Adv Chem Sci 2013;2(1):46-9.
18. Laxmi Bharghavi A, Maheshwari M, Kartheek N, Ashok kumar A. RP-HPLC method development and validation for the quantitative estimation of acamprosate calcium in tablets. Int J Pharm Pharm Sci 2014;6(6):2014.
19. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use. Validation of Analytical Procedures: Text and Methodology ICH Q2 (R1);2005.
Statistics
370 Views | 1222 Downloads
How to Cite
Nimma, J., R. Tuniki, S. K. Andela, S. Gadpale, and A. K. Akuthota. “METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTITATIVE ESTIMATION OF ACAMPROSATE CALCIUM IN TABLETS USING RP-HPLC”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 6, no. 10, 1, pp. 88-91, https://innovareacademics.in/journals/index.php/ijpps/article/view/1399.
Section
Original Article(s)